StockpollyBeta
Get App
Delisting riskPopularity #4,622
VXRT · NASDAQ · Biotechnology

Vaxart (VXRT)

Clinical-stage biotech developing oral tablet vaccines for infectious disease.

$0.4699
After hours−0.01 (−1.07%)
At close$0.4750(−1.06%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue23265152140721043927
Cost of revenue110000000000
Gross profit12265152140721043927
191926231927365480493440
Research & development151519171523315076452934
557544554457
General & administrative557544554457
Other expenses−1−10000000000
Operating income−18−17−24−16−14−11−15−15−8555−13
000000−100000
Interest income111011000111
Interest expense011111111111
Other non-operating income−1−1−10−1−1000−1−10
Income before tax−17−17−24−16−14−12−15−15−8555−13
Income tax expense000000000000
Net income from continuing operations−17−17−24−16−14−12−16−15−8555−13
Net income−17−17−24−16−14−12−16−15−8555−13
EPS, basic−$0.04−$0.10−$0.14−$0.09−$0.08−$0.05−$0.07−$0.07−$0.04$0.23$0.02−$0.06
EPS, diluted−$0.04−$0.10−$0.14−$0.09−$0.08−$0.05−$0.07−$0.07−$0.04$0.23$0.02−$0.06
Weighted average shares, basic487177177177177228228228229230241242
Weighted average shares, diluted487177177177177228228228229230242242
EBITDA−16−15−21−14−11−9−12−12−5587−12
Depreciation & amortization112222222211
EBIT−17−16−24−16−13−11−14−14−8566−13